← Leaderboards
Monte Meier Winslow
Massachusetts Institute Of Technology
$16,973,411
Attributed
$22,471,875
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,471,875 · 15
By mechanism
R01$16,997,721 · 8
U01$3,110,824 · 2
R21$775,376 · 2
R00$717,556 · 1
R61$645,827 · 1
K99$224,571 · 1
Top collaborators
- Dmitri A Petrov14 shared
- Katerina Abigail Politi5 shared
- Xiaojing J Gao3 shared
- Matthew S Bogyo2 shared
- Nathan Edward Reticker-Flynn1 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Forest M White$24,390,292
- Manolis Kellis$46,984,324
- Kevin Michael Haigis$17,260,553
- Michael B Yaffe$28,748,219
- Joseph Kissil$14,348,310
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorMalignant NeoplasmsMalignant Neoplasm Of LungMolecularMouse ModelCancer CellGenesPathway InteractionsCell LinePositioning AttributeMutationGenetically Engineered MouseLung NeoplasmsGene FunctionGrowthMediatingCancer ModelCrispr/Cas TechnologyTumor GrowthBaseCellsGenomicsEnvironment
Grant awards (58)
Multiplexed dissection of metastatic ability, organ tropism, and immune evasion$640,760
U01 · FY2025 · CA · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$551,847
R01 · FY2025 · CA
Dissecting the interplay between aging, genotype and the microenvironment in lung cancer$440,509
U01 · FY2025 · AG · contact PI
Genetic dissection of oncogenic Kras signaling$428,454
R01 · FY2025 · CA · contact PI
Program the Immune System against RAS-driven Cancer$219,956
R61 · FY2025 · CA
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$536,716
R01 · FY2024 · CA
Dissecting the interplay between aging, genotype and the microenvironment in lung cancer$457,145
U01 · FY2024 · AG · contact PI
Genetic dissection of oncogenic Kras signaling$415,768
R01 · FY2024 · CA · contact PI
Program the Immune System against RAS-driven Cancer$207,879
R61 · FY2024 · CA
Genetic analysis of aging on immune responses to lung cancer$156,018
U01 · FY2024 · AG · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$558,923
R01 · FY2023 · CA
Dissecting the interplay between aging, genotype and the microenvironment in lung cancer$464,561
U01 · FY2023 · AG · contact PI
Unraveling mechanisms of tumor suppression in lung cancer$431,227
R01 · FY2023 · CA · contact PI
Genetic dissection of oncogenic Kras signaling$428,170
R01 · FY2023 · CA · contact PI
Program the Immune System against RAS-driven Cancer$217,992
R61 · FY2023 · CA
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$561,463
R01 · FY2022 · CA
Dissecting the interplay between aging, genotype and the microenvironment in lung cancer$471,751
U01 · FY2022 · AG · contact PI
Unraveling mechanisms of tumor suppression in lung cancer$468,496
R01 · FY2022 · CA · contact PI
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo$446,368
R01 · FY2022 · CA · contact PI
Genetic dissection of oncogenic Kras signaling$437,856
R01 · FY2022 · CA · contact PI
Molecular dissection of Lkb1-mediated tumor suppression$409,805
R01 · FY2022 · CA · contact PI
Genetic Determinants of Tumor Growth and Drug Sensitivity in EGFR Mutant Lung Cancer$604,225
R01 · FY2021 · CA
Unraveling mechanisms of tumor suppression in lung cancer$490,735
R01 · FY2021 · CA · contact PI
Dissecting the interplay between aging, genotype and the microenvironment in lung cancer$480,080
U01 · FY2021 · AG · contact PI
Genetic dissection of oncogenic Kras signaling$468,244
R01 · FY2021 · CA · contact PI
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo$461,991
R01 · FY2021 · CA · contact PI
Molecular dissection of Lkb1-mediated tumor suppression$418,167
R01 · FY2021 · CA · contact PI
Unraveling mechanisms of tumor suppression in lung cancer$498,341
R01 · FY2020 · CA · contact PI
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo$461,991
R01 · FY2020 · CA · contact PI
Molecular dissection of Lkb1-mediated tumor suppression$418,167
R01 · FY2020 · CA · contact PI
Molecular Dissection of an Arntl2 induced pro-metastatic secretome$368,257
R01 · FY2020 · CA · contact PI
Unraveling mechanisms of tumor suppression in lung cancer$504,679
R01 · FY2019 · CA · contact PI
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo$457,548
R01 · FY2019 · CA · contact PI
Molecular dissection of Lkb1-mediated tumor suppression$411,941
R01 · FY2019 · CA · contact PI
Molecular Dissection of an Arntl2 induced pro-metastatic secretome$356,780
R01 · FY2019 · CA · contact PI
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer$554,387
R01 · FY2018 · CA · contact PI
(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivo$471,700
R01 · FY2018 · CA · contact PI
Molecular dissection of Lkb1-mediated tumor suppression$428,592
R01 · FY2018 · CA · contact PI
Molecular Dissection of an Arntl2 induced pro-metastatic secretome$367,403
R01 · FY2018 · CA · contact PI
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer$554,387
R01 · FY2017 · CA · contact PI
Molecular Dissection of an Arntl2 induced pro-metastatic secretome$367,019
R01 · FY2017 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$331,185
R01 · FY2017 · CA · contact PI
A Quantitative Multiplexed Platform for the Pharmacogenomic Analysis of Lung Cancer$554,387
R01 · FY2016 · CA · contact PI
Molecular Dissection of an Arntl2 induced pro-metastatic secretome$366,664
R01 · FY2016 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$330,972
R01 · FY2016 · CA · contact PI
Somatic Engineering-based Models of Pancreatic Cancer$177,884
R21 · FY2016 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$328,874
R01 · FY2015 · CA · contact PI
Somatic Engineering-based Models of Pancreatic Cancer$212,580
R21 · FY2015 · CA · contact PI
Multiplexed in vivo drug screening: Inhibitors of metastatic seeding$175,167
R21 · FY2015 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$319,310
R01 · FY2014 · CA · contact PI
Functional Characterization of Hmga2 in Lung Cancer Progression$237,269
R00 · FY2014 · CA · contact PI
Multiplexed in vivo drug screening: Inhibitors of metastatic seeding$209,745
R21 · FY2014 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$97,233
R01 · FY2014 · CA · contact PI
Molecular Dissection of Lung Cancer Progression and Metastasis$329,449
R01 · FY2013 · CA · contact PI
Functional Characterization of Hmga2 in Lung Cancer Progression$234,060
R00 · FY2013 · CA · contact PI
Functional Characterization of Lung Adenocarcinoma Progression and Metastasis$246,227
R00 · FY2012 · CA · contact PI
Functional Characterization of Lung Adenocarcinoma Progression and Metastasis$113,466
K99 · FY2011 · CA · contact PI
Functional Characterization of Lung Adenocarcinoma Progression and Metastasis$111,105
K99 · FY2010 · CA · contact PI